Anviron
Making Good Medicine
ABOUT US
According to the National Center for Advancing Translation Sciences, there are 7,000 identified rare diseases and 95% have no approved therapies. Anviron specializes in partnering with world-class research institutions, identifying and securing the most promising orphan disease therapies, and developing these therapies for difficult to treat illnesses.
We are a team of entrepreneurial and passionate scientists, doctors, and clinicians that are dedicated to bringing promising therapies to light.
IN THE NEWS
Sept 23, 2020 - University of California San Diego & Anviron announce agreement to exclusively license to commercialize novel natural regulatory T-Cell stimulators shown to reduce chronic and acute vacillatory conditions in vitro.
Oct 27, 2020 - University of California San Diego Innovator Spotlight, Bradley Morrison Founder
Dec 28, 2020 - University of Tennessee Research Foundation & Anviron announce agreement to an exclusive, world-wide license to commercialize a novel low toxicity DPAGT-1 inhibitor with demonstrated in vivo efficacy against pancreatic cancer tumors.
Feb 16, 2021 - Translational Research at UCSD Tackles Inflammatory Disease With Promise of a New Peptide Therapeutic - Anviron license partner, the University of California, San Diego, has identified Fc peptides that promote adaptive immune regulation and provide a novel alternative to current inflammatory disease therapeutics.
Mar 18, 2021 - UTRF, UTHSC, and Anviron Partner to Commercialize Novel Treatment for Pancreatic Cancer - The University of Tennessee Research Foundation, the University of Tennessee Health Science Center and biotech therapeutics startup Anviron recently announced a partnership to commercialize a novel product candidate with promising efficacy against pancreatic cancer tumors.
Oct 12, 2021 - The United States Food and Drug Administration (FDA) has granted “Orphan Drug Designation” to our drug candidate ANV221 for the treatment of pancreatic cancers. This important milestone confers the benefit of seven (7) years of market exclusivity in the United States and validates the team’s hard work toward developing a promising therapy for this difficult to treat disease.